Sarepta Therapeutics, Inc. short interest in 2023
In 2023, Sarepta Therapeutics, Inc.'s disclosed short interest ran from 7.03% of shares outstanding on 13 Jan 2023 to 5.02% on 29 Dec 2023, a change of -2.01 percentage points. The year's high was 9.20% on 28 Feb 2023 and its low 4.02% on 15 May 2023, averaging 5.48% across 24 twice-monthly settlement dates. FINRA's days-to-cover figure peaked at 8.55 days on 15 Feb 2023. Full history: Sarepta Therapeutics, Inc..
Cite this page
By year: 2018 · 2019 · 2020 · 2021 · 2022 · 2023 · 2024 · 2025 · 2026
2023 in figures
- Start of year
- 7.03% (13 Jan 2023)
- End of year
- 5.02% (29 Dec 2023)
- Change
- -2.01 pp
- High
- 9.20% (28 Feb 2023)
- Low
- 4.02% (15 May 2023)
- Average
- 5.48%
- Highest days to cover
- 8.55 (15 Feb 2023)
- SEC filings marked
- 5
Every report in 2023
| Settlement | Short interest | Days to cover | Filings since previous |
|---|---|---|---|
| 13 Jan 2023 | 7.03% | 5.68 | results (8-K) |
| 31 Jan 2023 | 7.66% | 6.91 | |
| 15 Feb 2023 | 8.60% | 8.55 | |
| 28 Feb 2023 | 9.20% | 7.68 | 10-K filed |
| 15 Mar 2023 | 6.20% | 2.35 | |
| 31 Mar 2023 | 5.37% | 2.50 | |
| 14 Apr 2023 | 5.10% | 3.01 | |
| 28 Apr 2023 | 4.40% | 4.02 | |
| 15 May 2023 | 4.02% | 1.67 | 10-Q filed |
| 31 May 2023 | 4.74% | 2.59 | |
| 15 Jun 2023 | 4.89% | 6.32 | |
| 30 Jun 2023 | 5.36% | 2.51 | |
| 14 Jul 2023 | 5.30% | 6.14 | |
| 31 Jul 2023 | 4.77% | 4.60 | |
| 15 Aug 2023 | 4.75% | 4.07 | 10-Q filed |
| 31 Aug 2023 | 4.94% | 5.48 | |
| 15 Sep 2023 | 4.84% | 5.97 | |
| 29 Sep 2023 | 5.17% | 5.61 | |
| 13 Oct 2023 | 5.24% | 4.73 | |
| 31 Oct 2023 | 4.75% | 1.62 | |
| 15 Nov 2023 | 4.54% | 1.85 | 10-Q filed |
| 30 Nov 2023 | 4.56% | 4.23 | |
| 15 Dec 2023 | 5.04% | 3.31 | |
| 29 Dec 2023 | 5.02% | 4.64 |
See also: Sarepta Therapeutics, Inc.'s full history · most shorted US stocks of 2023 · today's US league.
About this data
US short interest data: FINRA (finra.org), shown as reported shares short divided by SEC-reported shares outstanding for each settlement date. FINRA® is a registered trademark of the Financial Industry Regulatory Authority, Inc. This site is not affiliated with or endorsed by FINRA or the SEC; displayed for personal reference, bulk redistribution is not permitted (see terms). Nothing here is investment advice. Method: methodology.